+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vericiguat"

Beta Blockers Global Market Report 2024 - Product Thumbnail Image

Beta Blockers Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Angiotensin Receptor Blockers (ARBs) Global Market Report 2024 - Product Thumbnail Image

Angiotensin Receptor Blockers (ARBs) Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Vericiguat is a novel drug class of cardiovascular drugs used to treat heart failure. It is a soluble guanylate cyclase (sGC) stimulator, which works by increasing the production of cyclic guanosine monophosphate (cGMP) in the body. This helps to relax the blood vessels, allowing more blood to flow to the heart and improving its function. Vericiguat is approved for use in adults with chronic heart failure with reduced ejection fraction (HFrEF). It is also being studied for use in other cardiovascular conditions, such as hypertension and coronary artery disease. Vericiguat is a relatively new drug class, and is currently only available from a few companies. These include Bayer, Novartis, and Merck. Other companies are also researching and developing vericiguat-based drugs, such as Pfizer, GlaxoSmithKline, and AstraZeneca. Show Less Read more